The SoCal Edge
In this episode of SoCal Edge, we sit down with Adam Watson, co-founder and CEO of MeCo Diagnostics, a San Diego-based biotech startup developing the only clinically validated biomarker test designed to match breast cancer patients with anti-fibrotic therapy. Adam shares the remarkable journey from cancer biology PhD student to startup founder, explaining how his dissertation research evolved into a venture-backed company aiming to unlock what he describes as a “seventh modality” of breast cancer treatment. The conversation explores how MeCo Diagnostics is taking an unconventional approach to oncology by repurposing existing anti-fibrotic drugs rather than developing entirely new therapies — with the potential to dramatically reduce both cancer recurrence and treatment costs. We also dive into: * Why the economics of cancer treatment are becoming unsustainable * The challenges of fundraising as a diagnostics company * How biotech founders tailor pitches differently for VCs, angels, and family offices * The realities of leaving academia and becoming a first-time CEO * Lessons learned from building a biotech startup with limited capital * The role EvoNexus and the San Diego biotech ecosystem played in the company’s growth * Founder loneliness, impostor syndrome, and the pressures of startup life * Why Adam believes many people underestimate how difficult entrepreneurship really is This episode offers a candid look at the intersection of biotech innovation, healthcare economics, and startup building — from someone trying to fundamentally rethink how cancer care is delivered. Reach out to Adam: https://www.linkedin.com/in/adam-watson-phd/
25 episodios
Comentarios
0Sé la primera persona en comentar
¡Regístrate ahora y únete a la comunidad de The SoCal Edge!